Shanghai Medicilon (SHSE:688202) ROE % Adjusted to Book Value: 0.75% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688202 Shanghai Medicilon Inc SHSE:688202
69 GF Score
Price ¥83.20
GF Value ¥45.80
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Shanghai Medicilon ROE % Adjusted to Book Value?

Shanghai Medicilon SHSE:688202 -1.12% 69 ROE % Adjusted to Book Value is 0.75% as of Mar. 2026. GuruFocus rates SHSE:688202 with a GF Score™ of 69/100 and a GF Value™ of ¥45.80 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Shanghai Medicilon's ROE % for the quarter that ended in Mar. 2026 was 3.21%. Shanghai Medicilon's PB Ratio for the quarter that ended in Mar. 2026 was 4.28. Shanghai Medicilon's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 0.75%.

Shanghai Medicilon ROE % Adjusted to Book Value Related Terms

Shanghai Medicilon ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Shanghai Medicilon's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Medicilon ROE % Adjusted to Book Value Chart

Shanghai Medicilon Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.01 1.99 -0.44 -7.49 -2.10

Shanghai Medicilon Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.34 0.13 -0.72 -7.05 0.75

SHSE:688202 vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Shanghai Medicilon's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Medicilon ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Medicilon's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Shanghai Medicilon's ROE % Adjusted to Book Value falls into.


SHSE:688202
69GF Score
Shanghai Medicilon Inc SHSE:688202
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Medicilon ROE % Adjusted to Book Value Calculation

Shanghai Medicilon's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-8.24% / 3.92
=-2.10%

Shanghai Medicilon's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=3.21% / 4.28
=0.75%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.75% mean?
Shanghai Medicilon (SHSE:688202) has a ROE % Adjusted to Book Value of 0.75% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Shanghai Medicilon and its competitors.
Is Shanghai Medicilon's ROE % Adjusted to Book Value too high?
Shanghai Medicilon's current ROE % Adjusted to Book Value is 0.75%. Overall, Shanghai Medicilon has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Medicilon's ROE % Adjusted to Book Value compare to VRTX and REGN?
Shanghai Medicilon's ROE % Adjusted to Book Value of 0.75% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Shanghai Medicilon and its competitors. Shanghai Medicilon's current ROE % Adjusted to Book Value is 0.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Medicilon stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Medicilon (SHSE:688202) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥45.80, compared to a current price of ¥83.20 — trading 81.7% above its estimated fair value. The current ROE % Adjusted to Book Value is 0.75%. Shanghai Medicilon's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Shanghai Medicilon (SHSE:688202), the current ROE % Adjusted to Book Value is 0.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Medicilon (SHSE:688202) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Medicilon stock appears to be overvalued. The current stock price of ¥83.20 is trading 81.7% above its estimated GF Value™ of ¥45.80. GuruFocus considers Shanghai Medicilon to be Significantly Overvalued.

Key valuation signals for SHSE:688202:

  • ROE % Adjusted to Book Value: 0.75%
  • GF Value™: ¥45.80 vs. price of ¥83.20 (81.7% above fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the SHSE:688202 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Medicilon Business Description

Address Lane 67, Libing Road, Building 5, Pilot Free Trade Zone, Shanghai, CHN, 201299
Shanghai Medicilon Inc is a comprehensive biomedical research and developemnt service company. It provides a full range of one-stop new drug development services for pharmaceutical companies and research institutions around the world in line with domestic and international reporting standards.
69GF Score

Get the complete analysis for SHSE:688202

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥83.20
Price
¥45.80
GF Value